|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
EBSCO_ocn978248007 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
170321s2017 nyua ob 001 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d EBLCP
|d N$T
|d OCLCF
|d AGLDB
|d IGB
|d AUW
|d BTN
|d MHW
|d INTCL
|d SNK
|d G3B
|d S8I
|d S8J
|d STF
|d D6H
|d M8D
|d OCLCQ
|d OCLCO
|d AJS
|d OCLCO
|d OCLCQ
|
| 066 |
|
|
|c (S
|
| 020 |
|
|
|a 9781536109542
|q (electronic bk.)
|
| 020 |
|
|
|a 1536109541
|q (electronic bk.)
|
| 020 |
|
|
|z 9781536109443
|
| 035 |
|
|
|a (OCoLC)978248007
|
| 050 |
|
4 |
|a RC267
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99/4
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Horizons in cancer research.
|n Volume 65 /
|c Hiroto S. Watanabe, editor.
|
| 264 |
|
1 |
|a New York :
|b Nova Science Publishers, Inc.,
|c 2017.
|
| 300 |
|
|
|a 1 online resource :
|b illustrations
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Horizons in cancer research ;
|v Vol. 65
|
| 505 |
8 |
|
|a HORIZONS IN CANCER RESEARCH VOLUME 65 ; HORIZONS IN CANCER RESEARCH VOLUME 65 ; CONTENTS ; PREFACE ; Chapter 1 HEALTH PROMOTING ACTIVITY OF MYRICETIN: A NATURAL FLAVONOID ; ABSTRACT; INTRODUCTION ; POTENTIAL HEALTH EFFECTS ; Antineoplastic Activity ; Mutagenic and Antimicrobial Activity ; Interactions with DNA/Antiatherosclerotic Activity ; Antiviral ; Antidiabetic ; Neuroprotectant ; Insilico Anticancer Activity of Myricetin ; ADME/T STUDIES ; CONCLUSION ; ACKNOWLEDGMENTS; REFERENCES ; Chapter 2 IS VASCULOGENIC MIMICRY A HALLMARK OF AN AGGRESSIVE TUMOR? ; ABSTRACT
|
| 505 |
8 |
|
|a ABBREVIATIONS INTRODUCTION; CLINICAL SIGNIFICANCE OF VASCULOGENIC MIMICRY ; VM BLOCKADE REDUCES TUMOR GROWTH RATE IN EXPERIMENTAL LUNG, BREAST, COLON, CERVICAL CANCER AND MELANOMA MOUSE MODELS ; VM INHIBITOR, LCS1269, RESTORES SENSITIVITY OF RESISTANT MELANOMA CELLS TO DNA-DAMAGING AGENTS; MELANOMA EDUCATES NON-CANCER CELLS TOWARDS VASCULOGENIC MIMICRY ; CONCLUSION ; ACKNOWLEDGMENTS ; REFERENCES ; Chapter 3 EDUCATED OPINION: BACTERIAL TOXINS AS A DIRECT CAUSE OF CANCER ; ABSTRACT; REFERENCES ; Chapter 4 IMMUNOLOGICAL ASPECTS OF STROMA IN OVARIAN CANCER ; ABSTRACT
|
| 505 |
8 |
|
|a Chapter 5 IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF SOLID TUMORS: A NEW KEY IN THE HANDS OF ONCOLOGISTS ABSTRACT ; INTRODUCTION ; THE BIOLOGY OF CTLA 4 ; THE BIOLOGY OF PD 1 PATHWAY ; DRUGS BLOCKING THE CTLA4 AND PD 1 PATHWAY ; MELANOMA ; Metastatic Setting ; Adjuvant Setting ; HEAD AND NECK CANCER ; BREAST CANCER ; UROLOGICAL CANCER ; LUNG CANCER ; Non-Small Cell Lung Cancer (NSCLC) ; Nivolumab ; Pembrolizumab ; Atezolizumab ; Durvalumab ; Avelumab; REFERENCES
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
0 |
|
|a Vendor-supplied metadata.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cancer
|x Research.
|
| 650 |
|
0 |
|a Cancer
|x Treatment.
|
| 650 |
|
6 |
|a Cancer
|x Recherche.
|
| 650 |
|
6 |
|a Cancer
|x Traitement.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x General.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Clinical Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Diseases.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Evidence-Based Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Internal Medicine.
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer
|x Research.
|2 fast
|0 (OCoLC)fst00845497
|
| 650 |
|
7 |
|a Cancer
|x Treatment.
|2 fast
|0 (OCoLC)fst00845538
|
| 700 |
1 |
|
|a Watanabe, Hiroto S.,
|e editor.
|
| 830 |
|
0 |
|a Horizons in cancer research ;
|v vol. 65.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1488073
|z Texto completo
|
| 880 |
8 |
|
|6 505-00/(S
|a 1. INTRODUCTION 1.1. Ovarian Epithelial Cancer ; 1.2. Stroma ; 1.2.1. Stromal and Tumor Growth ; 1.3. Immunological Aspects and Cellular Constituents ; 1.3.1. Pericytes ; 1.3.2. Endothelial Cells; 1.3.3. Vascular Endothelial Growth Factor (VEGF) ; 1.3.4. Extracellular Matrix ; 1.3.5. Tumor-Associated Macrophages(TAMs) ; 1.3.6. Cancer Associated Fibroblasts (CAFs) ; 1.3.6.1. Fibroblast Activation Protein (FAP) ; 1.3.6.2. Alpha Smooth Muscle Actin (α-SMA) ; 1.4. Stroma in Ovarian Cancer ; CONCLUSION; REFERENCES
|
| 880 |
8 |
|
|6 505-00/(S
|a CD40 AS A TYPICAL NF-κB ACTIVATOR IN MULTIPLE MYELOMA CELLS
|
| 880 |
8 |
|
|6 505-00/(S
|a Chapter 6 NON-CODING MITOCHONDRIAL RNAS (NCMTRNAS) IN GYNECOLOGICAL AND URINARY MALIGNANCIES: UNIVERSAL TARGETS FOR DEVELOPMENT OF AN EFFICIENT THERAPYABSTRACT ; INTRODUCTION ; IMMUNE CHECKPOINTS INHIBITORS FOR UROLOGICAL AND GYNECOLOGICAL CANCERS ; LONG NONCODING RNAS IN GYNECOLOGICAL AND URINARY MALIGNANCIES ; THE NEW KIDS ON THE BLOCK: LONG NONCODING MITOCHONDRIAL NONCODING RNAS ; ACKNOWLEDGMENTS ; REFERENCES; Chapter 7 THE NF- κB SIGNALING PATHWAY AND ITS TARGETING IN HUMAN CANCER TREATMENT ; ABSTRACT ; INTRODUCTION ; NF-κB PROTEINS AND THEIR SIGNALING PATHWAYS
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4825355
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1488073
|
| 994 |
|
|
|a 92
|b IZTAP
|
